REGNClinical Trials•globenewswire•
Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
Sentiment:Positive (70)
Summary
Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 26, 2025 by globenewswire